Schedule a Meeting
Download Brochure
Table of Content
March 2025
The global topical drugs CDMO market size is calculated at US$ 46.32 in 2024, grew to US$ 51.62 billion in 2025, and is projected to reach around US$ 136.71 billion by 2034. The market is expanding at a CAGR of 11.43% between 2025 and 2034. Rising skin-related diseases are driving the growth of the topical drugs CDMO market.
Unlock Infinite Advantages: Subscribe to Annual Membership
A drug that is given to a specific area of the body is known as a topical medication. Topical medicine, which includes a wide variety of classes such as foams, foams, creams, gels, lotions, and ointments, is often applied to bodily surfaces like the skin or mucous membranes to treat illnesses. Novel studies employing penetration-enhancing technologies, including sonophoresis, iontophoresis, electroporation, microneedles, and others, show promise for these medications' successful introduction into clinical practice as transdermal, consumer-friendly dose forms.
The topical medications services provided by contract development and manufacturing organizations for the creation and production of topical pharmaceutical medications are referred to as CDMO. The demands of the pharmaceutical and biotechnology sectors are met by these CDMO services. Help is given with medication development, manufacturing procedures, and drug marketing. Additionally, there is a greater requirement for expanded outsourcing. These CDMOs also offer clinical trial material manufacture and research and development services.
Drug repurposing, de novo drug creation, biomarker identification, and personalized medicine are just a few of the drug discovery applications that artificial intelligence demonstrates. AI is also capable of detecting drug interactions that might cause negative responses or varied effects between medications intended to treat the same or different conditions. Drug development also heavily relies on molecular modeling, virtual screening, data integration and analysis, deep learning methods, and machine learning algorithms. Scientists can now forecast the toxicity and effectiveness of possible therapeutic molecules thanks to the incorporation of AI in medicinal chemistry. AI is also capable of finding patterns and trends in huge datasets of known medication interactions. The interactions between new drug pairings may be precisely and accurately predicted by machine learning systems.
Growing Cosmetic Procedures
There are many different types of medicines and topical treatments utilized in the wide field of cosmetic medicine. In addition to driving the need for CDMO services, the expansion of the aesthetic and cosmetic sectors increased the demand for topical medications. Topical anti-aging creams, skin-lightening agents, and scar reduction treatments are among the goods that are becoming increasingly popular in the topical medicine CDMO market. Additionally, topical medications help with pain relief, wound healing, and systemic diseases.
Challenges Faced During Formulations
It can be quite difficult to create topical formulations that are both stable and effective. Achieving the proper release profile, stability, drug solubility, and compatibility with excipients are some of the issues that make formulation creation complicated. The availability and economic feasibility of topical medicinal solutions may be impacted by these formulation issues since the formulation must provide optimal therapeutic effectiveness while meeting strict quality standards and regulatory constraints.
Precise Drug Formulations
A topical pharmaceutical CDMO creates formulations that are specific to the needs of each application, with an emphasis on treating a wide range of therapeutic indications, including dermatology, pain management, wound healing, and more. To achieve the intended therapeutic profile while preserving product stability and user-friendliness, the procedure entails the careful selection and balance of excipients and active pharmaceutical ingredients (APIs).
By product type, the semi-solid formulations segment dominated the topical drugs CDMO market in 2024. The majority of dose formulations used topically are semi-solid. Gels, creams, and ointments are examples of semi-solid formulations that are intended for use on the skin or mucous membranes, including the oral cavity. These compositions protect and hydrate the skin while also acting as a medium for phage delivery. Semi-solid formulas are easy to apply, often wash off with water, and don't irritate the skin too much. New treatment options are made possible by the capacity to construct a variety of APIs into semi-solid forms. It increases the medications' accessibility and adaptability to various patient requirements.
By product type, the liquid formulations segment is estimated to grow significantly in the topical drugs CDMO market during the forecast period. The simplicity of administration and quick and effective medication absorption have been used as justifications for the use of liquid drugs. Compared to solid dose forms, liquid dosage forms allow the medicine to be absorbed more easily. A quicker therapeutic response can be achieved by supplying the medication in solution, which will bypass the dissolving stage of the absorption process.
By service type, the contract manufacturing segment led the topical drugs CDMO market in 2024. A business may create its goods more easily and with less overhead when it uses contract manufacturing. Finding a reliable contract manufacturing partner to create the items for sale or the parts for assembly is all that is required of a business after it has a completed prototype. Utilizing the technical know-how of the manufacturer is an additional advantage of contract manufacturing. Businesses with inadequate resources or an excessive workload may now outsource product manufacturing thanks to contract manufacturers. For businesses that lack the necessary internal resources or wish to grow more quickly than they can on their own, they can offer specialized, technical manufacturing knowledge.
By service type, the contract development segment is estimated to grow at a lucrative rate in the topical drugs CDMO market during the forecast period. CDMOs, in contrast to other pharmaceutical service providers, are unique in that they integrate manufacturing and drug development skills under a single contract. A CDMO facilitates a variety of operations, including the creation of active pharmaceutical ingredients (APIs), formulation, upscaling, clinical trial management, regulatory compliance, and commercial manufacturing. CDMOs help streamline processes by utilizing cutting-edge technologies and comprehensive development services. This enables pharmaceutical and biotech companies to meet strict regulatory requirements while reducing costs and improving their time to market entry.
By end-use, the pharmaceutical companies segment dominated the topical drugs CDMO market in 2024. Pharmaceutical firms' growing reliance on outsourcing for medication research and manufacture is the reason for their drug pipeline expansions. To address the rising incidence of skin conditions, these companies are fortifying their pharmacological pipelines, which will increase demand for topical treatments. More cooperation with CDMOs that possess the infrastructure, expertise, and ability to promptly satisfy market demands without sacrificing quality has resulted from both of these causes. Pharmaceutical businesses may save money and overcome the difficulties of in-house manufacturing, including regulatory compliance, having the proper production technology, scaling production, and many other issues, by outsourcing CDMO.
By end-use, the biopharmaceutical companies segment is estimated to achieve significant CAGR in the topical drugs CDMO market during the predicted timeframe. The main cause of the high growth is the increasing number of biopharmaceutical businesses making investments in the creation and manufacturing of topical medications for a range of illnesses. Targeted medication delivery, the possibility of less systemic adverse effects, and the growing need for non-invasive therapeutic options are some of the drivers driving these expenditures. The pharmaceutical industry's continuous investment in topical formulations highlights the rising need for patient-friendly, efficacious topical therapy solutions.
Asia Pacific dominated the topical drugs CDMO market in 2024. Cost-effectiveness is a crucial factor in this region's supremacy. A number of Asia-Pacific nations, including China and India, provide affordable manufacturing options. Pharmaceutical firms find it appealing to outsource the manufacturing of topical drugs to CDMOs in the region because of lower labor and operating expenses, which leads to considerable cost savings. Additionally, the pharmaceutical drug sector is growing quickly in a number of Asian nations due to the growing need for novel pharmaceuticals and the expansion of healthcare requirements. Pharmaceutical firms are now searching for trustworthy regional CDMO partners as a result of this expansion. Therefore, it is expected that the previously mentioned variables will contribute to the region's profitable expansion.
China has the biggest market share in the topical medication delivery sector and is the nation with the quickest rate of growth in the healthcare sector. China's growing healthcare industry, fast urbanization, and sizable population are all factors contributing to the market's expansion. Many Chinese businesses are concentrating on taking advantage of the growing need for effective and efficient topical medication delivery systems.
The market for CDMOs in India is expected to expand rapidly. India's cost advantages over China and its dominant position in the production of generic drugs and active pharmaceutical ingredients (API) are the main drivers of this increase. Requests for Proposals (RFPs) have increased by 50% year over year for some Indian CDMOs in 2024 as international pharmaceutical companies seek to diversify their supply chains outside of China. Indian pharmaceutical services are a competitive alternative since they are priced 20% less than their Chinese equivalents. Innovative drug modalities are becoming more prevalent in the biopharmaceutical industry, and in the next ten years, they are predicted to surpass conventional small-molecule medications.
Latin America is estimated to host a significantly growing topical drugs CDMO market during the forecast period. Due to increasing disposable money brought forth by Latin America's economic progress, more individuals may now buy topical drugs and specialist cosmetic dermatological goods. Brazil is renowned for its thriving cosmetics and beauty sector. Topical products, particularly those for cosmetic and therapeutic uses, are in high demand throughout the nation. Therefore, it is expected that this increase in demand will spur regional growth.
One of Latin America's most significant pharmaceutical industries is expected to be Brazil. The demand for medicines in Brazil has been steadily rising due to a number of factors, including the country's aging population, growing healthcare expenses, and more public awareness of healthcare issues. Strict regulations have been put in place by the Brazilian government to encourage domestic pharmaceutical manufacturing. This covers regulations such as tax exemptions and benefits for products made in the country.
Mexico is Latin America's second-largest market for medical devices and goods. The healthcare industry in Mexico is a significant market for a wide range of goods and services. The nation's public health system recently experienced a number of modifications to its distribution and procurement framework. A large variety of both branded and generic drugs are produced in Mexico's booming pharmaceutical sector. The Federal Commission for Protection against Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios, or COFEPRIS) oversees the pharmaceutical industry.
North America is estimated to achieve steady growth in the topical drugs CDMO market during the estimated timeframe. The extensive use of cutting-edge topical treatments is supported by the area's established healthcare system. Access to state-of-the-art medical technology and high healthcare costs are factors driving market expansion. The increasing prevalence of dermatological disorders in North America fuels the need for potent topical therapies. Another factor driving up the usage of topical formulations is the rising prevalence of chronic illnesses like diabetes and arthritis. Many of the biggest pharmaceutical firms in the area make significant investments in the study and creation of innovative topical drug delivery methods.
The market was controlled by the US. Top production centers for extremely complicated, dependable, and expensive drugs are to blame for this. Additionally, biopharmaceutical businesses are concentrating on the U.S. market because of the nation's thriving healthcare sector, which contributes significantly to its market revenue. Among the main factors driving market expansion are topical medication firms' increased outsourcing strategies and CDMOs' assistance in cutting capital and operating costs. Additionally, the nation's robust R&D procedures and the development of novel treatments have greatly boosted the United States' sizeable market share. Additionally, the country's market is expected to grow as a result of the necessity to retain high client satisfaction in the face of fierce competition.
Over the course of the projection period, Canada is expected to see a steady growth rate. Increased investments, collaborations, and other strategic efforts by CDMOs that start research on skin illnesses to treat a range of dermatological and skin-related ailments are driving developments in Canada's pharmaceutical and biopharmaceutical industry. Furthermore, it is crucial for the nation to do research on topical and transdermal medication delivery methods.
In September 2023, according to Abhay Gandhi, CEO of Sun Pharma North America, the company is thrilled to introduce this highly anticipated and cutting-edge topical treatment for the millions of Canadians who suffer from acne. The introduction of WINLEVI expands Sun Pharma's line of specialized products in Canada and demonstrates our dedication to offering cutting-edge dermatological treatments that meet the requirements of our patients.
By Product Type
By Service Type
By End-use
By Region
March 2025
March 2025
February 2025
February 2025
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts